Tag Archives: hematologic cancers

June, 2018

29 June
FDA Lifts Clinical Hold on APTO-253, Aptose’s Investigational Drug for Hematological Cancers

SAN DIEGO and TORONTO, June 29, 2018 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that it has lifted the clinical hold on APTO-253, Aptose’s investigational drug for hematologic cancers. APTO-253 is the only known clinical-stage …
Share

8 December
bluebird bio and TC BioPharm Collaborate to Develop Gamma Delta CAR T Cell Products for Cancer Immunotherapy

CAMBRIDGE, Mass. & EDINBURGH, Scotland–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) and Scottish immunotherapy company TC BioPharm, Ltd. (TCB) today announced a strategic collaboration and license agreement focused on gamma delta CAR T cells. The companies will work together to advance TC BioPharm’s lead CAR-engineered gamma delta T cell program into clinical …
Share

22 April
AbbVie and CytomX Announce Collaboration for Probody Drug Conjugates

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV) and CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). CD71 is highly …
Share